YOLFTbeta
SY

SynAct Pharma AB

SYNACT · ST · Healthcare / Biotechnology

13.22SEK-2.76 (-17.27%)

Price History

Full chart

Market Stats

Previous Close15.98
Open15.38
Day Range12.98 – 15.48
52-Week Range7.05 – 25.30
Volume484.27K
Market Cap962.05M
P/E (TTM)0.00
Forward P/E0.00
EPS-2.05
Dividend Yield0.00%
Beta0.79
50-Day Avg18.73
200-Day Avg18.34

About

SynAct Pharma AB, a clinical stage biotechnology company, researches and develops medicines for the treatment of inflammatory diseases in Sweden. The company develops AP1189, a drug candidate in Phase 2 clinical trial for the treatment of rheumatoid arthritis; host targeted treatment for viral infections such as respiratory infections, dengue virus, as well as polymyalgia rheumatica (PMR); and idiopathic membranous nephropathy. It is also developing TXP-11, an advanced peptide agonist that is in preclinical trials for the prevention of organ failure in surgery; and various drug programs to treat auto-immune and inflammatory diseases. SynAct Pharma AB was founded in 2012 and is headquartered in Lund, Sweden.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Jeppe Ovli Ovlesen EE, MBA
  • Employees8
  • HeadquartersScheelevAegen 2, Lund, Sweden, 223 63, Sweden
  • Websitehttps://synactpharma.com

Leadership

  • Mr. Jeppe Ovli Ovlesen EE, MBAChief Executive Officer · b. 1962
  • Ms. Ann Kristin LedChief Financial Officer
  • Dr. Thomas Boesen Ph.D.Chief Operating Officer
  • Ms. Kristen Harting M.D.Chief Medical Officer
  • Mr. Mads BjerregaardChief Business Officer
  • Ms. Malin WikstrandFinancial Controller

Financials

Income Statement

Currency: SEK2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue----00000000
Cost of Revenue--190.36K252.02K303.57K338.51K-88.00K1.06M778.00K617.00K-
Gross Profit---190.36K-252.02K-303.57K-338.51K--88.00K-1.06M-778.00K-617.00K0
Operating Expense--16.78M17.94M28.09M24.46M-76.61M104.64M223.72M89.36M117.15M
Operating Income-501.00K-473.00K-16.97M-18.19M-28.39M-24.80M-31.29M-76.70M-105.70M-224.50M-89.98M-117.15M
EBITDA-418.00K-388.00K-16.80M-17.94M-27.94M-26.77M-30.90M-76.62M-105.71M-222.70M-15.40M-116.52M
Net Income-937.00K-982.00K-15.46M-15.40M-23.45M-23.96M-26.55M-69.30M-99.20M-215.81M-82.40M-110.83M
R&D216.00K324.00K--21.81M15.17K22.79M60.49M70.07M105.06M49.31M85.61M
Interest Expense---155.39K146.66K2.39M39.00K105.00K294.00K797.00K820.00K2.45M

Balance Sheet

Currency: SEK2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets723.00K377.00K30.57M15.23M14.03M23.81M21.59M38.37M142.60M228.02M270.52M220.52M
Total Liabilities81.00K57.00K3.49M2.31M3.72M10.31M5.72M17.50M16.08M51.83M56.35M50.23M
Total Equity-3.96M-4.79M27.08M12.91M10.31M13.50M15.87M20.87M126.52M176.19M214.17M170.29M
Cash253.00K42.00K26.57M10.21M7.12M3.56M14.55M24.00M108.25M62.40M61.21M53.41M
Total Debt-------3.09M2.06M637.00K1.88M1.81M
Net Debt-253.00K-42.00K-26.57M-10.21M-7.12M-3.56M-14.55M-20.91M-106.18M-61.76M-59.33M-51.60M

Cash Flow

Currency: SEK2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow---14.73M-17.20M-24.21M-16.12M-33.24M-65.00M-117.56M-100.18M-89.20M-97.33M
Investing Cash Flow---996.14K-264.50K-93.00K-499.00K-93.00K-6.00K27.00K370.00K--
Financing Cash Flow--42.13M950.89K20.76M13.00M44.72M74.32M200.71M53.98M87.41M90.46M
Capital Expenditure00902.96K264.50K0499.00K33.24M00000
Free Cash Flow---15.64M-17.47M-24.21M-16.62M-33.24M-65.00M-117.56M-100.18M-89.20M-97.33M
FCF to OCF--106.13%101.54%100.00%103.09%100.00%100.00%100.00%100.00%100.00%100.00%

Earnings

Report DateSep 30, 2016Dec 31, 2016Mar 31, 2017Jun 30, 2017Sep 30, 2017Dec 31, 2017Mar 31, 2018Jun 30, 2018Sep 30, 2018Feb 11, 2019Apr 24, 2019Aug 30, 2019Sep 30, 2019Jan 6, 2020Apr 9, 2020Sep 10, 2020Nov 13, 2020Feb 12, 2021May 5, 2021Aug 27, 2021Nov 12, 2021Feb 11, 2022May 30, 2022Aug 5, 2022Nov 4, 2022Feb 17, 2023May 5, 2023Aug 4, 2023Oct 24, 2023Feb 23, 2024Apr 24, 2024Aug 20, 2024Oct 30, 2024Feb 18, 2025May 27, 2025Aug 20, 2025Oct 30, 2025Feb 19, 2026May 28, 2026Aug 20, 2026
EPS Estimate-----------------------------0.76-0.76----------
EPS Actual-0.15-0.57-0.25-0.30-0.14-0.43-0.22-0.57-0.42-0.39-0.25-0.40-0.20-0.61-0.26-0.25-0.33-0.35-0.46-0.50-0.70-1.00-0.77-0.91-0.84-1.06-1.59-1.37-1.00-2.58-0.70-0.47-0.49-0.44-0.51-0.56-0.67-0.43-0.48-0.39
Surprise-----------------------------31.58%-239.47%----------
Timing---------Pre-market---After-hoursPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-market--Pre-marketPre-market-----

Key Statistics & Ratios

Market Cap962.05M
Enterprise Value970.03M
Trailing P/E0.00
Forward P/E0.00
Price / Sales0.00
Price / Book5.73
EPS-2.05
Book Value3.07
Revenue (TTM)0
Gross Profit (TTM)0
EBITDA-116.28M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-57.67%
Return on Assets-31.25%
Shares Outstanding56.00M
Shares Float37.83M
Beta0.79
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%